Hormonal
GLP-1 receptor agonists reduce albuminuria and slow eGFR decline in non-diabetic patients with CKD, particularly those who are obese.
If you have kidney disease and are obese but do not have diabetes, ask your doctor about GLP-1 receptor agonists like semaglutide. Early evidence suggests these medications can significantly reduce albuminuria, a marker of kidney damage, even in non-diabetic patients. However, more research is needed to confirm long-term kidney outcomes in this group.
Complementing the renal benefits disclosed in the SELECT trial, Apperloo et al examined the effect of semaglutide in non-diabetic obese patients with CKD. Treatment with semaglutide for 24 weeks was found to reduce albuminuria by 52% when compared to placebo.
Why this rating
Based on a single study (Apperloo et al) and secondary analyses, with no large-scale kidney outcome trials in non-diabetic patients yet.
Source
Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease
Kavya Rajan et al. · International Journal of Nephrology and Renovascular Disease · 2026
DOI 10.2147/ijnrd.s522424
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) significantly slow chronic kidney disease (CKD) progression and reduce mortality in patients with type 2 diabetes and CKD.Strong
- GLP-1 receptor agonists provide additive kidney benefits when used in combination with SGLT2 inhibitors, addressing residual cardiorenal risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →